PMID- 22544534
OWN - NLM
STAT- MEDLINE
DCOM- 20121108
LR  - 20211203
IS  - 1534-6293 (Electronic)
IS  - 1528-4042 (Print)
IS  - 1528-4042 (Linking)
VI  - 12
IP  - 4
DP  - 2012 Aug
TI  - Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, 
      antiepileptogenic, and epileptostatic therapy.
PG  - 410-8
LID - 10.1007/s11910-012-0276-5 [doi]
AB  - New epilepsy treatments are needed that not only inhibit seizures symptomatically 
      (antiseizure) but also prevent the development of epilepsy (antiepileptogenic). 
      The mammalian target of rapamycin (mTOR) pathway may mediate mechanisms of 
      epileptogenesis and serve as a rational therapeutic target. mTOR inhibitors have 
      antiepileptogenic and antiseizure effects in animal models of the genetic 
      disease, tuberous sclerosis complex. The mTOR pathway is also implicated in 
      epileptogenesis in animal models of acquired epilepsy and infantile spasms, 
      although the effects of mTOR inhibitors are variable depending on the specific 
      conditions and model. Furthermore, beneficial effects on seizures are lost when 
      treatment is withdrawn, suggesting that mTOR inhibitors are "epileptostatic" in 
      only stalling epilepsy progression during treatment. Clinical studies of 
      rapamycin in human epilepsy are limited, but suggest that mTOR inhibitors at 
      least have antiseizure effects in tuberous sclerosis patients. Further studies 
      are needed to assess the full potential of mTOR inhibitors for epilepsy 
      treatment.
FAU - Ryther, Robin C C
AU  - Ryther RC
AD  - Department of Neurology and the Hope Center for Neurological Disorders, 
      Washington University School of Medicine, Box 8111, 660 South Euclid Avenue, St. 
      Louis, MO 63110, USA. rytherr@neuro.wustl.edu
FAU - Wong, Michael
AU  - Wong M
LA  - eng
GR  - R01 NS056872/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Neurol Neurosci Rep
JT  - Current neurology and neuroscience reports
JID - 100931790
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Brain Injuries/*drug therapy
MH  - Disease Models, Animal
MH  - Humans
MH  - Seizures/*drug therapy
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/*metabolism
MH  - Tuberous Sclerosis/*drug therapy
PMC - PMC3875462
MID - NIHMS539728
EDAT- 2012/05/01 06:00
MHDA- 2012/11/09 06:00
PMCR- 2013/12/30
CRDT- 2012/05/01 06:00
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2012/11/09 06:00 [medline]
PHST- 2013/12/30 00:00 [pmc-release]
AID - 10.1007/s11910-012-0276-5 [doi]
PST - ppublish
SO  - Curr Neurol Neurosci Rep. 2012 Aug;12(4):410-8. doi: 10.1007/s11910-012-0276-5.